Is a Shorter Trastuzumab Duration a Cost-Effective Option in HER2+ Breast Cancer?

Researchers compared the cost effectiveness of two durations of trastuzumab in HER2+ breast cancer patients.

Source: CancerNetwork - November 1, 2018 Category: Cancer & Oncology Authors: Dave Levitan Source Type: news